drugset / Trial / NCT00095719
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
Phase 3
Completed
125 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
Timeline
- Start
- 2003-12
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 2.5 mg | Intramuscular |
| Comparator | Aripiprazole | Other / unclassified | 5 mg | Intramuscular |
| Comparator | Aripiprazole | Other / unclassified | 10 mg | Intramuscular |